Evidence map›Paper›PMID 38339479›Full record

ArticleSensors (Basel, Switzerland)2024

Validation of a Zio XT Patch Accelerometer for the Objective Assessment of Physical Activity in the Atherosclerosis Risk in Communities (ARIC) Study.

Anis Davoudi, Jacek K Urbanek, Lacey Etzkorn, Romil Parikh, Elsayed Z Soliman, Amal A Wanigatunga, Kelley Pettee Gabriel, Josef Coresh, Jennifer A Schrack, Lin Yee Chen

Open access · goldAbstract read
In one paragraph

Article in Sensors (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 1 country.

Anis DavoudiBloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA.ORCID 0000-0002-3383-9481
Jacek K UrbanekRegeneron Pharmaceuticals Inc., Tarrytown, NY 10591, USA.
Lacey EtzkornBloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA.ORCID 0000-0001-7107-2763
Romil ParikhSchool of Public Health, University of Minnesota, Minneapolis, MN 55455, USA.ORCID 0000-0001-6087-0583
Elsayed Z SolimanSection on Cardiovascular Medicine, Department of Medicine, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA.
Amal A WanigatungaBloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA.ORCID 0000-0002-5763-5184
Kelley Pettee GabrielSchool of Public Health, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Josef CoreshBloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA.
Jennifer A SchrackBloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA.ORCID 0000-0001-9244-9267
Lin Yee ChenMedical School, University of Minnesota, Minneapolis, MN 55455, USA.
Johns Hopkins University · USRegeneron (United States) · USUniversity of Alabama at Birmingham · USUniversity of Minnesota · USUniversity of Minnesota Medical Center · USWake Forest University · US

Funding

THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY - COORDINATING CENTER - TASK AREA B.2 AND B.375N92022D00001 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI COUPER, DAVID · 2022 to 2025
$13.7M
THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY - FIELD CENTER - TASK ORDER 01, TASK AREA A75N92022D00003 · NHLBI · UNIVERSITY OF MINNESOTA · PI LUTSEY, PAMELA L. · 2022 to 2025
$5.1M
THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY - FIELD CENTER - TASK ORDER 01, TASK AREA A75N92022D00005 · NHLBI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI WAGENKNECHT, LYNNE E · 2022 to 2025
$5.0M
THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY - FIELD CENTER - TASK ORDER 01, TASK AREA A75N92022D00004 · NHLBI · UNIVERSITY OF MISSISSIPPI MED CTR · PI WINDHAM, BEVERLY GWEN · 2022 to 2025
$4.8M
THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY - FIELD CENTER - TASK ORDER 01, TASK AREA A75N92022D00002 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI CORESH, JOSEF · 2022 to 2025
$4.7M
Significance of Atrial Fibrillation and Atrial Fibrillation Burden Detected by Novel ECG Monitoring in Community-Dwelling ElderlyR01HL126637 · NHLBI · UNIVERSITY OF MINNESOTA · PI CHEN, LIN YEE · 2016 to 2020
$3.7M
The START trial: a proof-of-concept sedentary reduction program for prefrail older adultsK01AG076967 · NIA · JOHNS HOPKINS UNIVERSITY · PI Amal Asiri Wanigatunga · 2022 to 2026
$651k
The Associations of Mid- and Late-Life Physical Activity on Falls in a Large Prospective Study of Older AdultsR56AG049886 · NIA · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI GABRIEL, KELLEY PETTEE, POMPEII, LISA A · 2015 to 2015
$542k
NHLBI NIH HHS 75N92022D00001NHLBI NIH HHS 75N92022D00002NHLBI NIH HHS 75N92022D00003NHLBI NIH HHS 75N92022D00004NHLBI NIH HHS 75N92022D00005NHLBI NIH HHS R01 HL126637NIA NIH HHS K01 AG076967NIA NIH HHS K01 G076967NIA NIH HHS R56 AG049886
6 · The paper itself

Abstract

backgroundCombination devices to monitor heart rate/rhythms and physical activity are becoming increasingly popular in research and clinical settings. The Zio XT Patch (iRhythm Technologies, San Francisco, CA, USA) is US Food and Drug Administration (FDA)-approved for monitoring heart rhythms, but the validity of its accelerometer for assessing physical activity is unknown.

objectiveTo validate the accelerometer in the Zio XT Patch for measuring physical activity against the widely-used ActiGraph GT3X.

methodsThe Zio XT and ActiGraph wGT3X-BT (Actigraph, Pensacola, FL, USA) were worn simultaneously in two separately-funded ancillary studies to Visit 6 of the Atherosclerosis Risk in Communities (ARIC) Study (2016-2017). Zio XT was worn on the chest and ActiGraph was worn on the hip. Raw accelerometer data were summarized using mean absolute deviation (MAD) for six different epoch lengths (1-min, 5-min, 10-min, 30-min, 1-h, and 2-h). Participants who had ≥3 days of at least 10 h of valid data between 7 a.m-11 p.m were included. Agreement of epoch-level MAD between the two devices was evaluated using correlation and mean squared error (MSE).

resultsAmong 257 participants (average age: 78.5 ± 4.7 years; 59.1% female), there were strong correlations between MAD values from Zio XT and ActiGraph (average

conclusionsThese findings suggest that Zio XT accelerometry is valid for measuring duration, frequency, and intensity of physical activity within time epochs of 5-min to 2-h.

Indexed as

AtherosclerosisExerciseAccelerometryAgedAged, 80 and overFemaleHumansMaleActiGraph GT3XvalidationwearablesZio XT Patch

Identifiers

PMID38339479
PMCPMC10857412
OpenAlexW4391168014

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.